R&D Collaboration

Zeon and CSIR-IIIM sign MoU for collaborative research on botanicals

Our Correspondent
Our Correspondent
Posted on 10 Mar 2022
19:15 PM
This collaboration fosters the market of botanical formulations that the institute has produced with scientific rationale.

This collaboration fosters the market of botanical formulations that the institute has produced with scientific rationale. Source: Pixabay

ADVERTISEMENT
Summary
The aim of this collaboration is to conduct joint research and strengthen research and development projects of mutual interest
The partnership will concentrate on product development in the areas of nutraceuticals, phytopharmaceuticals, and Ayurvedic medicine

Zeon Lifesciences, an Indian manufacturer of nutraceutical and herbal products, has signed a memorandum of understanding (MoU) with the Council of Scientific and Industrial Research - Indian Institute of Integrative Medicine (CSIR-IIIM) - Jammu for innovative research programmes.

The aim of this collaboration is to conduct joint research and strengthen research and development projects of mutual interest.

Zeon will focus on the innovative botanical formulations for various critical care (viz: Neurological Disorder, Anticancer, Immunity Booster and diabetic care). In addition, this collaboration fosters the market of botanical formulations that the institute has produced with scientific rationale. The partnership will concentrate on product development in the areas of nutraceuticals, phytopharmaceuticals, and Ayurvedic medicine. On mutually agreed terms and conditions, Zeon and CSIR-IIIM will conduct clinical studies in accordance with AYUSH or DCGI Guidelines for chosen formulations.

ADVERTISEMENT

Commenting on the collaboration, Suresh Garg, founder & MD of Zeon, said, “We believe that the industry-academia-collaboration is essential for fostering creativity and developing novel solutions that benefit society. Naturally, we work in the therapeutic areas of nutraceuticals and wellness. Our organisation is primarily concerned with the management of neurological disorders and collaborates closely with the CSIR-IIIM. Following that, we'll undertake some preclinical and clinical investigations at Zeon utilising their facilities for unique in-house formulations."

Last updated on 10 Mar 2022
19:15 PM
ADVERTISEMENT
Read Next